Trials / Completed
CompletedNCT00098345
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 (vandetanib) | oral once daily tablet |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2008-02-01
- Completion
- 2017-04-19
- First posted
- 2004-12-08
- Last updated
- 2018-05-07
- Results posted
- 2011-05-24
Locations
6 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT00098345. Inclusion in this directory is not an endorsement.